Skip to main content
. 2016 Apr 14;75(10):1006–1015. doi: 10.1007/s00393-016-0071-9

Fig. 2.

Fig. 2

Cost-effectiveness acceptability curve for the base case scenario. The curve shows the percentage of simulated patients, whose treatment with adalimumab combination therapy would fulfill a specific incremental cost-utility ratio (ICUR), which the regulator can define